I understand that Ray, that's why I remain long, and CYTR is not about GBM, that's a freebie
the CR is real, proven by mass reduction surgery. tumor did not die on its own. but not to worry Rindo has a lock on GBM. I am good either way. 34.5 cytr 10.5 cldx
yes one down - but there is always that sneaky aldox that had a CR in GBM. with a PII ongoing. a second CR if it happens in hat study will change the game.
Why sit on it if its a simple "CYTR has been accepted for a late breaking ..." PR.
Shareholders deserve to know now.
question is if they were turned down why would that be? nothing new is the likely answer.
no more than 12 patients in GBM study and "several" now becomes a number of 3 or 4 then its nothing new. they could update for time but is that new enough for ASCO if its only 4 months. it should be.
bottom line is she you nothing, right?
its either late breaking or nothing at this point. does not mean CYTR cannot come out with a PR around ASCO instead of an abstract at ASCO.
that is certainly the expectation. but then there is the reputation of the CEO that we need to factor in
Asia PT is my call. within 2 months.
then if ASCO news good and or a PT is announce the run continues.
do you expect to see another CR ? they submitted interim GB and Kaposi for presentation at ASCO couple of months back. they did not announce completing enrollment of the 28 cohort GBM study. with a CR one would think completion would be a no brainer, yet no update?
the guy with the CR actually withdrew due to side effects. perhaps the side effects are impacting enrollment?
Oppy coverage - the start of legitimacy.
pps has doubled last few months.
they had a complete response in GBM PII that the market has ignored but if if they get another market will take notice. and this is not the value driver.
33k shares and adding
the guy withdrew from the study due to side effects of aldox. not sure what to make of that other than he was a lucky man that a single dose resulted in a CR.